CN114601838B - Application of AZD8055 in preparation of medicine for resisting adenovirus infection - Google Patents
Application of AZD8055 in preparation of medicine for resisting adenovirus infection Download PDFInfo
- Publication number
- CN114601838B CN114601838B CN202210475162.5A CN202210475162A CN114601838B CN 114601838 B CN114601838 B CN 114601838B CN 202210475162 A CN202210475162 A CN 202210475162A CN 114601838 B CN114601838 B CN 114601838B
- Authority
- CN
- China
- Prior art keywords
- adenovirus
- azd8055
- treating
- infection
- adenovirus infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 72
- KVLFRAWTRWDEDF-IRXDYDNUSA-N AZD-8055 Chemical compound C1=C(CO)C(OC)=CC=C1C1=CC=C(C(=NC(=N2)N3[C@H](COCC3)C)N3[C@H](COCC3)C)C2=N1 KVLFRAWTRWDEDF-IRXDYDNUSA-N 0.000 title claims abstract description 60
- 208000010370 Adenoviridae Infections Diseases 0.000 title claims abstract description 49
- 206010060931 Adenovirus infection Diseases 0.000 title claims abstract description 48
- 208000011589 adenoviridae infectious disease Diseases 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 241000701161 unidentified adenovirus Species 0.000 claims abstract description 60
- 239000003937 drug carrier Substances 0.000 claims abstract description 4
- 238000011282 treatment Methods 0.000 claims description 13
- 239000002552 dosage form Substances 0.000 claims description 12
- 239000007924 injection Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000006208 topical dosage form Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 230000010076 replication Effects 0.000 abstract description 11
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 150000001875 compounds Chemical class 0.000 abstract description 5
- 231100000252 nontoxic Toxicity 0.000 abstract description 3
- 230000003000 nontoxic effect Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 54
- 229940079593 drug Drugs 0.000 description 40
- 210000003501 vero cell Anatomy 0.000 description 25
- 241000700605 Viruses Species 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 8
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 230000003263 anti-adenoviral effect Effects 0.000 description 7
- 239000003443 antiviral agent Substances 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 210000000234 capsid Anatomy 0.000 description 7
- 230000003833 cell viability Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 230000000840 anti-viral effect Effects 0.000 description 6
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 6
- 238000010166 immunofluorescence Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 238000004364 calculation method Methods 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 108090000565 Capsid Proteins Proteins 0.000 description 4
- 102100023321 Ceruloplasmin Human genes 0.000 description 4
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 4
- 239000013504 Triton X-100 Substances 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000012148 binding buffer Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012827 research and development Methods 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241001135569 Human adenovirus 5 Species 0.000 description 3
- 241000193096 Human adenovirus B3 Species 0.000 description 3
- 241000598171 Human adenovirus sp. Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 238000005138 cryopreservation Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 206010001257 Adenoviral conjunctivitis Diseases 0.000 description 2
- 108700026758 Adenovirus hexon capsid Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 238000000116 DAPI staining Methods 0.000 description 2
- 101710145505 Fiber protein Proteins 0.000 description 2
- 241000701149 Human adenovirus 1 Species 0.000 description 2
- 241000701190 Human adenovirus 11 Species 0.000 description 2
- 241000701131 Human adenovirus 14 Species 0.000 description 2
- 241001135567 Human adenovirus 40 Species 0.000 description 2
- 241000701137 Human adenovirus 41 Species 0.000 description 2
- 241000701096 Human adenovirus 7 Species 0.000 description 2
- 241001135572 Human adenovirus E4 Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 101710173835 Penton protein Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 101710118538 Protease Proteins 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000021373 epidemic keratoconjunctivitis Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 201000006476 shipyard eye Diseases 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 241001160050 Bat mastadenovirus Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010755 Conjunctivitis viral Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 101710141836 DNA-binding protein HU homolog Proteins 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 101710094396 Hexon protein Proteins 0.000 description 1
- 101150032643 IVa2 gene Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 101710173438 Late L2 mu core protein Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710174628 Modulating protein YmoA Proteins 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 101710177319 Protamine-like protein Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 208000005914 Viral Conjunctivitis Diseases 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000002737 cell proliferation kit Methods 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 229960000724 cidofovir Drugs 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- -1 small molecule compound Chemical class 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of biomedicine, and discloses application of AZD8055 in preparation of a medicament for resisting adenovirus infection, wherein the medicament for relieving and/or preventing and/or treating adenovirus infection acts by inhibiting adenovirus replication activity. Adenoviruses are various types of adenoviruses including, but not limited to, the AdV3 subtype and the AdV5 subtype. The medicaments for alleviating and/or preventing and/or treating adenovirus infection comprise AZD8055 and a pharmaceutically acceptable carrier. The invention provides an application of a small molecular compound AZD8055 in preparing medicaments for treating adenovirus infection, and provides a safe and effective small molecular compound for treating adenovirus clinically. AZD8055 can effectively inhibit the replication of adenovirus in a non-toxic range, can be further developed into a medicament for treating diseases caused by adenovirus infection, and has wide application prospect.
Description
Technical Field
The invention belongs to the technical field of biomedicine, and particularly relates to application of AZD8055 in preparation of a medicine for resisting adenovirus infection.
Background
Currently, human adenoviruses (HAdV) belong to the genus mammalian adenoviruses of the family adenoviridae. Adenovirus is a non-enveloped icosahedral nucleocapsid DNA virus whose genome is cored by a linear double stranded DNA molecule, approximately 36kb, and whose genome is packaged in high concentration and organized into chromatin by hundreds of histone-like proteins VII and protamine-like proteins Mu (also known as protein X). The capsid of adenovirus has 240 hexon proteins (hexon) and 12 peaks of the icosahedral capsid are complexes of pentameric (penton) and trimeric (fiber) proteins. The 12 fiber proteins protrude from the capsid surface on the basis of the penton protein, and the fiber tips form the knob region (knob). The knob region of the penton and fiber proteins can bind to viral receptors on the cell surface and play a very important role in the viral infection of cells. Smaller capsid proteins IIIa, VI, VIII and IX are embedded in the capsid, wherein capsid protein VI is located on the inner surface of the capsid and the capsid is linked to the core comprising the viral genome by capsid protein V. There is also a small number of capsid proteins IVa2 in the capsid involved in genome packaging and adenovirus protease (AVP) formation.
Adenovirus infection can occur in any season, but often winter and early spring are peak seasons of viral infection. Human adenoviruses are classified into seven of a, B, C, D, E, F and G, 57 serotypes in total, based on serum neutralization, hemagglutination epitopes, genomic sequences and function. The types of adenovirus which are popular in China mainly comprise type 1, type 3, type 4, type 5, type 7, type 11, type 14, type 40, type 41 and type 55, wherein the types of adenovirus flow mainly comprise type 3 adenovirus flow and type 5 adenovirus flow. The adenovirus types were found to be highly conserved in the genome except for the hexon, fiber, penton genes, and rarely undergo intraspecies recombination. Therefore, the method is favorable for overcoming the limitation of the specificity of the medicaments on adenovirus types, and antiviral medicaments which are usually aimed at adenovirus entering the later stage have broad-spectrum anti-adenovirus activity in adenovirus seeds.
Adenovirus infection has a variety of clinical symptoms and disease manifestations, which depend largely on the adenovirus type, the host's immune status and the site of infection. Common sites of infection for adenoviruses include the respiratory tract, corneal epithelium, and intestinal tract. 90% of cases of viral conjunctivitis are caused by adenovirus infection, usually associated with B, D or type E adenovirus infection, often in the form of conjunctivitis pharyngeal or Epidemic Keratoconjunctivitis (EKC) in new soldiers on the line. B. Adenovirus type D or E also often causes acute respiratory illness and viral pneumonia. Two more serious consequences of respiratory adenovirus infection are pneumonia, which can be fatal in children. And acute respiratory distress syndrome, are more common among the symptomatic panelists. Adenoviruses of types a, F and G are associated with gastrointestinal infections. Adenovirus infection is the main cause of gastroenteritis in children, second only to norovirus and rotavirus. In general, adenoviruses are susceptible to all groups of people, where more severe diseases and even death can often occur in infected newborns, children, and immunocompromised groups (hematopoietic stem cells and organ transplant patients).
There is currently no antiviral drug approved for the treatment of adenovirus infection. Certain DNA/RNA synthesis inhibiting antiviral drugs (e.g., cidofovir, ganciclovir Wei Heli bavin) approved for the treatment of other viral infections have been used clinically to treat severe adenovirus infections as trial drugs by expanding the indications. However, most of these drugs have limited efficacy and serious adverse effects. Thus, there is a need to develop other safer and more effective anti-adenovirus drugs.
AZD8055 is a potential novel therapeutic agent for treating lymphomas, solid tumors and gliomas, is a novel and effective mTOR inhibitor, and can inhibit proliferation of various human tumor cell lines. AZD8055 inhibits migration, invasion and epithelial-mesenchymal transition of tumor cells by inhibiting the abnormally activated PI3K/Akt/mTOR signaling pathway of the tumor cells, and simultaneously participates in regulating angiogenesis and immune response in the Tumor Microenvironment (TME), so that the tumor regresses. However, no relevant report on the treatment of adenovirus infection by AZD8055 has been found at present.
Through the above analysis, the problems and defects existing in the prior art are as follows:
(1) There is no report on the treatment of adenovirus infection by AZD 8055.
(2) The prior art has low drug effect and poor effect on the medicaments for treating adenovirus infection.
Disclosure of Invention
Aiming at the problems existing in the prior art, the invention provides an application of AZD8055 in preparing medicaments for resisting adenovirus infection.
The invention is achieved by the use of AZD8055 in the manufacture of a medicament for the alleviation and/or prophylaxis and/or treatment of an adenovirus infection.
Further, the structural formula of the AZD8055 is as follows:
further, the adenovirus includes adenovirus type B, subtype AdV3, adenovirus type C, subtype AdV5.
Further, the adenovirus is one or more of human adenovirus type 1, type 3, type 4, type 5, type 7, type 11, type 14, type 40, type 41 and type 55.
Further, the agent for alleviating and/or preventing and/or treating adenovirus infection acts by inhibiting the activity of adenovirus replication.
Further, the medicament for alleviating and/or preventing and/or treating adenovirus infection comprises AZD8055 and a pharmaceutically acceptable carrier.
Further, the dosage form of the medicament for relieving and/or preventing and/or treating adenovirus infection is any clinically acceptable oral administration dosage form, injection administration dosage form or external administration dosage form.
Further, the medicine for relieving and/or preventing and/or treating adenovirus infection is tablets, capsules, granules, oral liquid and injection.
It is another object of the present invention to provide the use of AZD8055 in the preparation of an adenovirus inhibitor.
In combination with the above technical solution and the technical problems to be solved, please analyze the following aspects to provide the following advantages and positive effects:
first, aiming at the technical problems in the prior art and the difficulty in solving the problems, the technical problems solved by the technical proposal of the invention are analyzed in detail and deeply by tightly combining the technical proposal to be protected, the results and data in the research and development process, and the like, and some technical effects brought after the problems are solved have creative technical effects. The specific description is as follows:
aiming at the current situation that no antiviral drug for adenovirus infection exists in the prior art, the invention provides a novel anti-adenovirus drug-AZD 8055 in combination with experimental data such as low cytotoxicity of AZD8055 in Vero cells, high antiviral activity on two adenoviruses and the like in the research and development process, provides a novel technology of the antiviral drug for adenovirus infection, and provides a brand new therapy and more treatment options for treating diseases caused by adenovirus infection.
The invention provides an application of a small molecular compound AZD8055 in preparing medicaments for treating adenovirus infection, and provides a safe and effective small molecular compound for treating adenovirus clinically. AZD8055 can effectively inhibit the replication of adenovirus in a non-toxic range, can be further developed into a medicament for treating diseases caused by adenovirus infection, and has wide application prospect.
AZD8055 of the invention is a small molecule compound that has not seen any cytotoxicity at 5 μm in Vero cells. Thus, CC 50 (half lethal concentration) greater than 5. Mu.M. AZD8055 is able to dose-dependently inhibit viral replication for both adenoviruses (AdV 3 and AdV 5). Its IC for AdV3 in Vero cells 50 (half inhibitory concentration) was only 0.11. Mu.M, IC for AdV5 50 0.16. Mu.M. By calculation, the Selection Index (SI) of AZD8055 was greater than 10 on both adenoviruses, demonstrating that AZD8055 has a broad spectrum of activity against adenovirus replication.
Secondly, the technical scheme is regarded as a whole or from the perspective of products, and the technical scheme to be protected has the following technical effects and advantages:
the invention provides a novel anti-adenovirus drug AZD8055, which overcomes the technical defect that the prior art does not have antiviral drugs aiming at adenovirus infection.
The AZD8055 of the invention is used as a novel antitumor drug in research and development, is in clinical test of stage I, and has a large amount of clinical safety experimental data. If the indication is expanded to the medication for treating adenovirus infection, the risk of failure of clinical safety test can be obviously reduced, and the development time and cost of new medicine are greatly saved.
Thirdly, as inventive supplementary evidence of the claims of the present invention, the following important aspects are also presented:
(1) The expected benefits and commercial values after the technical scheme of the invention is converted are as follows: the invention takes the clinical requirement as the guide, focuses on the core treatment field, is based on clinical value, pharmaceutical economy value and commercial value of products, and has huge commercial value and expected benefit after transformation
(2) The technical scheme of the invention fills the technical blank in the domestic and foreign industries: the invention provides a novel technology of antiviral drugs for adenovirus infection.
Drawings
FIG. 1 shows that Vero cells according to the examples of the invention contain 5% CO at 37℃with AZD8055 in different concentration gradients 2 After 48 hours incubation in an incubator, the measured cell viability of Vero cells relative to untreated cells;
FIG. 2 is a graph showing the percentage of inhibition of AdV3 in Vero cells treated with different drug concentration gradients relative to non-drug-loaded cells after viral infection, after addition of AZD8055 in different concentration gradients to Vero cells provided in the examples of the present invention, infection of AdV3 with MOI 0.55, incubation at 37℃for 48 hours;
FIG. 3 is a graph showing the percentage of inhibition of AdV5 in Vero cells treated with different drug concentration gradients relative to untreated virus cells after incubation at 37deg.C for 48 hours by adding AZD8055 in different concentration gradients to Vero cells provided in the examples of the present invention to AdV5 infected with MOI 1.1.
Detailed Description
The present invention will be described in further detail with reference to the following examples in order to make the objects, technical solutions and advantages of the present invention more apparent. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the scope of the invention.
1. The embodiments are explained. In order to fully understand how the invention may be embodied by those skilled in the art, this section is an illustrative embodiment in which the claims are presented for purposes of illustration.
The application of the AZD8055 provided by the embodiment of the invention in preparing medicaments for relieving and/or preventing and/or treating adenovirus infection and adenovirus inhibitors.
The AZD8055 provided by the embodiment of the invention has the following chemical structural formula:
the adenovirus provided by the embodiment of the invention can be any one or more of human adenovirus type 1, type 3, type 4, type 5, type 7, type 11, type 14, type 40, type 41 and type 55.
The drugs for alleviating and/or preventing and/or treating adenovirus infection provided by the embodiments of the present invention act by inhibiting the activity of adenovirus replication.
The medicine for relieving and/or preventing and/or treating adenovirus infection provided by the embodiment of the invention comprises AZD8055 and a pharmaceutically acceptable carrier.
The dosage form of the medicine for relieving and/or preventing and/or treating adenovirus infection provided by the embodiment of the invention is any clinically acceptable oral administration dosage form, injection administration dosage form or external administration dosage form.
The medicine for relieving and/or preventing and/or treating the adenovirus infection provided by the embodiment of the invention is tablets, capsules, granules, oral liquid and injection.
2. Application example. In order to prove the inventive and technical value of the technical solution of the present invention, this section is an application example on specific products or related technologies of the claim technical solution.
The AZD8055 provided by the embodiment of the invention is applied to the preparation of medicaments for relieving and/or preventing and/or treating adenovirus infection and adenovirus inhibitors. AZD8055 can effectively inhibit the replication of adenovirus in a non-toxic range, can be further developed into a medicine for treating diseases caused by adenovirus infection, and has wide application prospect. In view of the fact that no drug for the treatment of adenovirus infection is currently approved for the market, the invention provides a new technology for the treatment of adenovirus infection.
3. Evidence of the effect of the examples. The embodiment of the invention has a great advantage in the research and development or use process, and has the following description in combination with data, charts and the like of the test process.
The invention detects the toxicity of AZD8055 to cells on an African green monkey kidney cell line Vero, and simultaneously determines the inhibition effect of AZD8055 to adenovirus type 3 (AdV 3) and adenovirus type 5 (AdV 5) in the Vero cell line. The results show that the small molecule compound AZD8055 has significant dose-dependent anti-adenovirus activity against both AdV3 and AdV5. Therefore, the AZD8055 provided by the invention is a novel antiviral drug for adenovirus, has the advantages of good safety, high selection index, broad-spectrum adenovirus resistance and the like, can be used for developing drugs for treating adenovirus infection, and has a wide application prospect.
1. Experimental materials:
(1) Cell lines, laboratory animals and viruses for laboratory purposes
Vero cells were purchased from American Type Culture Collection (ATCC);
strains used: adenovirus type B AdV3, adenovirus type C AdV5.
The required drugs for the experiment: AZD8055 is available from Selleck Chemicals company; in cell experiments, the drug was dissolved in DMSO.
Reagents required for the experiment:
DMEM medium, fetal Bovine Serum (FBS) were purchased from GIBCO;
CellTiter-Glo cell proliferation assay kit was purchased from Promega corporation.
(2) Instrument for experiment
Enspire multifunctional microplate reader available from Perkinelmer company;
CO 2 cell incubator was purchased from Thermo company;
the operaetta CLS high content imaging analysis system was purchased from PerkinElmer corporation.
2. Experimental method
2.1 Cytotoxicity assays for AZD8055 were as follows:
(1) Vero was used as a 2X 10 Vero cell line 4 Each well was plated into 96-well plates and incubated for 24h.
(2) Adding AZD8055 diluted with culture medium to different gradient concentrations, and adding 5% CO at 37deg.C 2 The culture was continued for 48 hours in the incubator of (C).
(3) Cell viability following treatment with different concentrations of drug was tested to detect cytotoxicity of AZD 8055.
(4) By usingGraphpad plots the relative Cell viability (Cell viability) versus the log of drug concentration, and calculates the half-Cytotoxicity Concentration (CC) of the drug 50 )。
2.2 evaluation of the antiviral activity of AZD8055 against adenovirus AdV3 in a cell model included:
(1) Vero was used as a 2X 10 Vero cell line 4 Each well was plated into 96-well plates and incubated for 24h. To examine its antiviral efficacy, vero cells were infected with adenovirus AdV3 at 0.55MOI (multiplicity of infection).
(2) Simultaneously adding AZD8055 diluted with culture medium to different gradient concentrations, and adding 5% CO at 37deg.C 2 The culture was continued for 48 hours in the incubator of (C).
(3) The number of virus-infected positive cells (Hexon positive cells) in the drug-treated and untreated cell wells was examined by indirect immunofluorescence experiments (Indirect immunofluorescence assay, IFA) to assess the replication level of adenovirus AdV3 after treatment with AZD8055 at different concentrations.
(4) The median Inhibitory Concentration (IC) of the drug against adenovirus AdV3 was calculated by plotting Graphpad against the log of the Inhibition rate (Inhibition rate) against the drug concentration 50 ). The selection index of AZD8055 on the Vero cell line for adenovirus AdV3 was calculated.
2.3 evaluation of the antiviral activity of AZD8055 on adenovirus AdV5 in cell model as follows:
1) Vero was used as a 2X 10 Vero cell line 4 Each well was plated into 96-well plates and incubated for 24h. To examine its antiviral effect, vero cells were infected with adenovirus AdV5 at 1.1MOI (multiplicity of infection).
2) Simultaneously adding AZD8055 diluted with culture medium to different gradient concentrations, and adding 5% CO at 37deg.C 2 The culture was continued for 48 hours in the incubator of (C).
3) The number of virus-infected positive cells (Hexon positive cells) in the drug-treated and untreated cell wells was examined by indirect immunofluorescence experiments (Indirect immunofluorescence assay, IFA) to assess the replication level of adenovirus AdV5 following treatment with AZD8055 at different concentrations.
4) Plotting the Inhibition rate (Inhibition rate) against the log of the drug concentrationThe median Inhibitory Concentration (IC) of the drug against adenovirus AdV5 was calculated 50 ). The selection index of AZD8055 on the Vero cell line for adenovirus AdV5 was calculated.
2.4 Evaluation of cytotoxicity of AZD8055 in Vero cell line
(1) Cell culture
Subjecting the cells after cryopreservation and resuscitation to 2 passages, and culturing with DMEM medium containing 10% foetal calf serum and double antibody (penicillin 100U/ml, streptomycin 100 μg/ml) at inoculation density of not less than 1x10 4 cell/ml, passage density not higher than 5x10 4 cell/ml。
(2) Drug-treated cells
Vero cells at 1X10 4 Cells/well (volume 100 μl) were inoculated into 96-well cell culture plates and cultured for 24h until cell well confluence reached 80%; 200 mu L of culture medium solution (DMEM culture medium+2% serum+double antibody) is used for preparing medicines per well, and the medicines are added into corresponding cell holes for uniform mixing. The drug was set to 8 concentration gradients, each gradient having 2 multiplex wells at final concentrations of 0.002. Mu.M, 0.007. Mu.M, 0.02. Mu.M, 0.06. Mu.M, 0.19. Mu.M, 0.56. Mu.M, 1.67. Mu.M and 5. Mu.M, containing 5% CO at 37 ℃C 2 The culture was continued for 48 hours in the incubator of (C).
(3) Calculating cytotoxicity of the drug in each assay well
The supernatant was removed and 100. Mu.L CellTiter-Reagents, plates were incubated for 10 min at room temperature to stabilize the luminescence signal. Chemiluminescent readings were measured using an EnSpire microplate reader and cell viability was calculated.
Cell viability (%) = drug treated/untreated control group 100%
As shown in FIG. 1, after the AZD8055 is treated with Vero cells for 48 hours at the highest concentration of 5. Mu.M, the cell viability is slightly different from that of the control group, which indicates that AZD8055 has weak toxicity to cells at the highest concentration, and half toxicity concentration CC 50 Greater than 5 μm.
2.5 Evaluation of AZD8055 against AdV3 adenovirus Activity in Vero cell line
(1) Cell culture
Subjecting the cells after cryopreservation and resuscitation to 2 passages, and culturing with DMEM medium containing 10% foetal calf serum and double antibody (penicillin 100U/ml, streptomycin 100 μg/ml) at inoculation density of not less than 1x10 4 cell/ml, passage density not higher than 5x10 4 cell/ml。
(2) Drug-treated cells
Vero cells at 1X10 4 Cells/well (volume 100 μl) were inoculated into 96-well cell culture plates and cultured for 24h until cell well confluence reached 80%; the infectious group was added with 0.55MOI (multiplicity of infection) of AdV3 virus, and simultaneously with each gradient of drug (5. Mu.M as starting concentration, 8 gradients were serially diluted 3-fold in a gradient, two duplicate wells per gradient) to a total volume of 200. Mu.L of culture medium (DMEM medium+2% serum+diabodies) and incubated in a cell incubator at 37℃for 48h.
(3) Indirect immunofluorescence method for detecting specific fluorescent-labeled virus
Cell culture plates were washed twice with PBS solution and fixed with 4% paraformaldehyde (4% pfa in PBS) for 20 min at room temperature. The fixed samples were washed 3 times with PBST (0.05% tween 20 in PBS) and then incubated in blocking buffer (3% BSA,0.3% Triton X-100 and 10% FBS in PBS) for 1 hour at room temperature. Then incubated overnight at 4℃in a binding buffer (PBS solution of 3%BSA,0.3%Triton X-100) against mouse monoclonal antibodies (diluted 1:200) to adenovirus hexon protein. After rinsing 3 times with PBST, the samples were incubated in goat FITC-conjugated anti-mouse secondary antibody (dilution 1:1000) and DAPI (dilution 1:10000) in binding buffer for 1 hour in the dark at room temperature. After rinsing 3 times with PBST, useCLS TM The high content analysis system observes the sample and then captures and analyzes the image.
(4) Calculating the inhibition rate of the drug in each detection hole to viruses
Cells were labeled by DAPI staining, FITC staining intensity representing the level of viral replication. FITC background fluorescence values were measured in uninfected control cells. Cells with FITC intensities three times higher than control cells were defined as adenovirus-infected positive cells. The ratio of adenovirus-infected positive cells in total cells was calculated.
Inhibition (%) = 100% - (drug treated well-blank)/(virus control well-blank) ×100%
As shown in FIG. 2, AZD8055 significantly inhibited replication of adenovirus AdV3 and was dose dependent with half the effective concentration of IC 50 0.11. Mu.M.
(5) Drug selection index calculation
The drug Selection Index (SI) is used to judge the safety range of the drug effect, and a selection index of more than 3 is effective, and the safety range is larger as the index is larger. The calculation formula is as follows: si=cc 50 /IC 50
In combination with the data, AZD8055 has a selection index of greater than 10 on Vero for adenovirus AdV3 and has effective anti-adenovirus AdV3 activity.
2.6 Evaluation of AZD8055 against AdV5 adenovirus Activity in Vero cell line
(1) Cell culture
Subjecting the cells after cryopreservation and resuscitation to 2 passages, and culturing with DMEM medium containing 10% foetal calf serum and double antibody (penicillin 100U/ml, streptomycin 100 μg/ml) at inoculation density of not less than 1x10 4 cell/ml, passage density not higher than 5x10 4 cell/ml。
(2) Drug-treated cells
Vero cells at 1X10 4 Cells/well (volume 100 μl) were inoculated into 96-well cell culture plates and cultured for 24h until cell well confluence reached 80%; the infectious group was added with 1.1MOI (multiplicity of infection) of AdV5 virus, and simultaneously with each gradient of drug (5. Mu.M as starting concentration, 8 gradients were serially diluted 3-fold in a gradient, two duplicate wells per gradient) to a total volume of 200. Mu.L of culture medium (DMEM medium+2% serum+diabodies) and incubated in a cell incubator at 37℃for 48h.
(3) Indirect immunofluorescence method for detecting specific fluorescent-labeled virus
Cell culture plates were washed twice with cells in PBS and at room temperatureThe mixture was then fixed with 4% paraformaldehyde (4% PFA in PBS) for 20 minutes. The fixed samples were washed 3 times with PBST (0.05% tween 20 in PBS) and then incubated in blocking buffer (3% BSA,0.3% Triton X-100 and 10% FBS in PBS) for 1 hour at room temperature. Then incubated overnight at 4℃in a binding buffer (PBS solution of 3%BSA,0.3%Triton X-100) against mouse monoclonal antibodies (diluted 1:200) to adenovirus hexon protein. After rinsing 3 times with PBST, the samples were incubated in goat FITC-conjugated anti-mouse secondary antibody (dilution 1:1000) and DAPI (dilution 1:10000) in binding buffer for 1 hour in the dark at room temperature. After rinsing 3 times with PBST, useCLS TM The high content analysis system observes the sample and then captures and analyzes the image.
(4) Calculating the inhibition rate of the drug in each detection hole to viruses
Cells were labeled by DAPI staining, FITC staining intensity representing the level of viral replication. FITC background fluorescence values were measured in uninfected control cells. Cells with FITC intensities three times higher than control cells were defined as adenovirus-infected positive cells. The ratio of adenovirus-infected positive cells in total cells was calculated.
Inhibition (%) = 100% - (drug treated well-blank)/(virus control well-blank) ×100%
As shown in FIG. 3, AZD8055 significantly inhibited replication of adenovirus AdV5 and was dose dependent with half the effective concentration of IC 50 0.16. Mu.M.
(5) Drug selection index calculation
The drug Selection Index (SI) is used to judge the safety range of the drug effect, and a selection index of more than 3 is effective, and the safety range is larger as the index is larger. The calculation formula is as follows: si=cc 50 /IC 50
In combination with the data, AZD8055 has a selection index of greater than 10 on Vero for adenovirus AdV5 and has potent anti-adenovirus AdV5 activity.
The foregoing is merely illustrative of specific embodiments of the present invention, and the scope of the invention is not limited thereto, but any modifications, equivalents, improvements and alternatives falling within the spirit and principles of the present invention will be apparent to those skilled in the art within the scope of the present invention.
Claims (6)
1. Use of AZD8055 in the manufacture of a medicament for the alleviation and/or prevention and/or treatment of an adenovirus infection;
the adenovirus is the AdV3 subtype of the B group adenovirus and the AdV5 subtype of the C group adenovirus.
2. The use according to claim 1, wherein the medicament for alleviating and/or preventing and/or treating an adenovirus infection comprises AZD8055 and a pharmaceutically acceptable carrier.
3. The use according to claim 1, wherein the dosage form of the medicament for alleviating and/or preventing and/or treating an adenovirus infection is any one of the clinically acceptable oral dosage forms.
4. The use according to claim 1, wherein the dosage form of the medicament for alleviating and/or preventing and/or treating an adenovirus infection is any one of the clinically acceptable injectable dosage forms.
5. The use according to claim 1, wherein the dosage form of the medicament for alleviating and/or preventing and/or treating an adenovirus infection is any one of the clinically acceptable topical dosage forms.
6. The use according to claim 1, wherein the medicament for alleviating and/or preventing and/or treating adenovirus infection is in the form of a tablet, capsule, granule, oral liquid, injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210475162.5A CN114601838B (en) | 2022-04-29 | 2022-04-29 | Application of AZD8055 in preparation of medicine for resisting adenovirus infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210475162.5A CN114601838B (en) | 2022-04-29 | 2022-04-29 | Application of AZD8055 in preparation of medicine for resisting adenovirus infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114601838A CN114601838A (en) | 2022-06-10 |
| CN114601838B true CN114601838B (en) | 2023-10-27 |
Family
ID=81869734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210475162.5A Active CN114601838B (en) | 2022-04-29 | 2022-04-29 | Application of AZD8055 in preparation of medicine for resisting adenovirus infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114601838B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105431157A (en) * | 2013-06-14 | 2016-03-23 | 普赛奥克苏斯治疗公司 | A dosing regime and formulations for type B adenoviruses |
| CN111727062A (en) * | 2018-01-31 | 2020-09-29 | 皮斯奥克斯治疗公司 | Formulations comprising group B adenoviruses |
| WO2021207632A1 (en) * | 2020-04-10 | 2021-10-14 | The Regents Of The University Of California | Small molecule therapeutics for the treatment of viral infections |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013500265A (en) * | 2009-07-23 | 2013-01-07 | ザ トラスティーズ オブ プリンストン ユニバーシティ | MTOR kinase inhibitor used as an antiviral agent |
| US9149445B2 (en) * | 2009-07-27 | 2015-10-06 | The Trustees Of Princeton University | Inhibition of glycerol-3-phosphate acyltransferase (GPAT) and associated enzymes for treatment of viral infections |
-
2022
- 2022-04-29 CN CN202210475162.5A patent/CN114601838B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105431157A (en) * | 2013-06-14 | 2016-03-23 | 普赛奥克苏斯治疗公司 | A dosing regime and formulations for type B adenoviruses |
| CN111727062A (en) * | 2018-01-31 | 2020-09-29 | 皮斯奥克斯治疗公司 | Formulations comprising group B adenoviruses |
| WO2021207632A1 (en) * | 2020-04-10 | 2021-10-14 | The Regents Of The University Of California | Small molecule therapeutics for the treatment of viral infections |
Non-Patent Citations (1)
| Title |
|---|
| ATP竞争性mTOR抑制剂研究进展;杨牛牛等;现代生物医学进展;第11卷(第24期);5159-5161 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114601838A (en) | 2022-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112457281B (en) | Small molecule inhibitor for blocking combination of COVID-19 spinous protein and human angiotensin converting enzyme 2 and application thereof | |
| CN114601838B (en) | Application of AZD8055 in preparation of medicine for resisting adenovirus infection | |
| CN108721293A (en) | Application of the ipecine in preparing wide spectrum anti-coronavirus drug | |
| CN114748482B (en) | Application of PF-04691502 in preparation of medicaments for resisting adenovirus infection | |
| CN114652727B (en) | Application of WYE-125132 in preparation of medicine for resisting adenovirus infection | |
| CN115400120B (en) | Application of Alvesbimycin in preparation of medicine for resisting adenovirus infection | |
| CN114767687B (en) | Application of Sapanisertib in preparation of medicine for resisting adenovirus infection | |
| CN115400121B (en) | Application of SNX-2112 in preparation of medicines for resisting adenovirus infection | |
| CN114917222B (en) | Application of Ganetespib in preparation of medicine for resisting adenovirus infection | |
| CN115400122B (en) | Application of TAK-632 in preparing medicine for resisting adenovirus infection | |
| CN115006395B (en) | Application of XL888 in preparation of medicine for resisting adenovirus infection | |
| CN115120594B (en) | Application of Zelavespib in preparation of medicine for resisting adenovirus infection | |
| Sun et al. | Inhibitory effects and mechanisms of proanthocyanidins against enterovirus 71 infection | |
| CN114681463B (en) | Application of HSP990 in preparing medicine for preventing and/or treating adenovirus infection | |
| CN114767671B (en) | Application of VER-49009 in preparation of medicaments for preventing and/or treating adenovirus infection | |
| CN113274484B (en) | Application of lentil agglutinin in preparing medicine for preventing and treating infectious diseases caused by coronavirus | |
| CN114948971A (en) | Application of Vissturtib in preparation of medicine for resisting adenovirus infection | |
| CN114652728A (en) | Application of Apitolisib in preparation of medicine for resisting adenovirus infection | |
| Wang et al. | In silico high-throughput screening system for AKT1 activators with therapeutic applications in sepsis acute lung injury | |
| CN114767686A (en) | Application of PF-04691502 in preparation of medicine for preventing and/or treating adenovirus infection | |
| CN111568900A (en) | Application of indomethacin in resisting coronavirus infection | |
| CN114652726A (en) | Application of BIIB021 in preparation of medicine for preventing and/or treating adenovirus infection | |
| CN114767683A (en) | Application of Onalesipi b in preparation of medicine for preventing and/or treating adenovirus infection | |
| CN114767689A (en) | Application of Luminespib in preparation of medicine for preventing and/or treating adenovirus infection | |
| CN114652731B (en) | Application of tannic acid in preparation of medicine for preventing and treating African swine fever |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |